Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.34 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.34 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.34 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.34 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.34 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 3/20 | 0.33 |
| ▸ | PPARA | Q07869 | 3/20 | 0.33 |
| ▸ | PNMT | P11086 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19464670 | 0.88 | MAPT (0.38) | LMNATP53HTTKCNH2CXCR3 | |
| SCHEMBL22932512 | 0.87 | PSEN1 (0.37) | LMNATP53HTTPSEN1PSEN2 | |
| SCHEMBL19121860 | 0.85 | LMNA (0.41) | LMNATP53HTTKCNH2CXCR3 | |
| SCHEMBL16117013 | 0.85 | LMNA (0.41) | LMNATP53HTTKCNH2CXCR3 | |
| SCHEMBL12735695 | 0.85 | LMNA (0.41) | LMNATP53HTTKCNH2CXCR3 | |
| SCHEMBL20365885 | 0.81 | TP53 (0.55) | LMNATP53HTTPSEN1PSEN2 | |
| SCHEMBL19098547 | 0.81 | MC4R (0.39) | SLC6A4PDE2A | |
| SCHEMBL21725496 | 0.81 | HTT (0.38) | LMNATP53HTTPSEN1PSEN2 | |
| SCHEMBL19987472 | 0.81 | KCNH2 (0.40) | LMNATP53HTTKCNH2CXCR3 | |
| SCHEMBL23084281 | 0.80 | LMNA (0.40) | LMNATP53HTTKCNH2PSEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150998-A1 | COMPOUNDS AS GLP-1R AGONISTS | Terns, Inc. | 2023-05-18 | — | — | US | disclosed |
| US-20210122757-A1 | SPIROCYCLIC COMPOUNDS AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | Phenex Discovery Verwaltungs-GmbH (DE) | 2021-04-29 | — | — | US | disclosed |
| US-10399932-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122757-A1 | SPIROCYCLIC COMPOUNDS AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, TPH1 | LMNA 3679/4885TP53 4291/4885HTT 913/4885 |
| US-10399932-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | IDO1, IDO2, INMT | LMNA 4373/4885TP53 352/4885HTT 3300/4885 |
| US-20230150998-A1 | COMPOUNDS AS GLP-1R AGONISTS | GLP1R, GIPR, GCGR | LMNA 2472/4885TP53 3988/4885HTT 780/4885 |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | IDO1, IDO2, INMT | LMNA 4373/4885TP53 352/4885HTT 3300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.